Live financial news intelligence

Track market-moving stories before they get noisy

Real-time pulse of financial headlines curated from 5 premium feeds.

Latest market signal Czech Filtered by asset IT

Coverage 166,249 Raw stories ingested 21,840 rewritten in CS_CZ • 8 to rewrite (last 2 days).

Symbols 2,793 Assets with fetched stories

Cryptocurrencies BTC 7,323 ETH 4,840 XRP 3,260 SOL 2,982 HYPE 1,746 USDC 1,589

Stocks NVDA 1,790 SPCX 1,455 MU 1,325 MSFT 1,296 AAPL 1,042 TSLA 1,026

Commodities GOLD 549 SILVER 293 OIL 101 PLATINUM 14 PALLADIUM 4 COPPER 3

Forex EURUSD 497 GBPUSD 376 USDCAD 149 USDJPY 144 AUDUSD 99 USDCHF 63

2,195 with rewritten stories in CS_CZ • Hot assets ranked by fetched stories.

Agents 7 Live Pipeline agents

FMP Stock News Fetch every minute 37s ago
FMP Forex News Fetch every 5 min 2m ago
CoinGecko News Fetch every 5 min 4m ago
FIO Stock News Fetch every 10 min 7m ago
Patria Stock News Fetch every 10 min 7m ago
Editorial rewrite Rewrite every minute running now
Asset sync Assets every 1 hour 46m ago

Latest coverage

Market News Feed

Scan headlines quickly, then expand any story for source context.

Category Source Ticker

Relevance

Clear

Details	Date	Content	Source	Relevance
	Saved 2026-09-08 17:32 23h ago Published 2026-09-08 06:00 1d ago	Gartner v srpnu vzrostl o 31,2 % po silných výsledcích Gartner v srpnu vzrostl o 31,2 % po lepších než očekávaných výsledcích za 2. čtvrtletí a zvýšení celoročního EPS na 14 USD. IT Gartner	FMP Stock News	78
Original source text Gartner (IT -5.93%) shareholders enjoyed a month of huge gains in August. The stock moved 31.2% higher in the period, according to data from S&P Global Market Intelligence. The broader market saw bullish momentum last month, with the S&P 500 up 2.6% and the Nasdaq Composite up 3.9%. But while the positive trading backdrop for the market at large helped support Gartner's gains, it was the company's better-than-expected second-quarter report that was the biggest catalyst. Image source: Getty Images. Gartner's Q2 report helped quiet fears surrounding the stock Gartner released its Q2 report before the market opened on Aug. 4, and the company's results and forward guidance were significantly better than expected. The research and information services specialist posted non-GAAP (adjusted) earnings per share of $4.37, exceeding the average analyst estimate by $0.64 per share. Revenue was still down 0.6% year over year at $1.68 billion, but it beat the average analyst target by roughly $50 million. Meanwhile, sales were actually up 2.8% using the company's adjusted comparison. Investors have been concerned that the business would face a challenging sales environment amid the rise of artificial intelligence, and there has been some evidence that the trend is pressuring demand. With indications that revenue is either stabilizing or seeing modest growth, depending on the comparison methodology, the Q2 sales performance provided some counter-indicators that these concerns may be overblown. Premium Feature Moneyball Superscore 63/100 Today's Change ( -5.93 %) $ -11.05 Current Price $ 175.37 Perhaps even more importantly, the big earnings beat in the quarter shows that the company was able to find areas for improved operational efficiency at a time when sales growth has been harder to come by. Net income increased 14.4% year over year to $275 million, and free cash flow was up 8.9% to $378 million. Gartner's guidance also spurred bullish sentiment With its Q2 report, Gartner raised its guidance for full-year earnings per share from $13.25 to $14. The company also hiked its FCF target to $1.19 billion -- up from $1.16 billion. While sales guidance was revised down to roughly $6.375 billion from roughly $6.405 billion due to currency headwinds, the stronger outlook on earnings was more than enough to offset the sales forecast shift in the eyes of investors. Gartner stock also had substantial short interest heading into the publication of its Q2 results, and the better-than-expected print for the quarter and forward guidance may have produced short covering that helped create a huge rally for its share price. The company still has to prove that it can sustain its earnings momentum, but its recent business update was reassuring given some of the concerns surrounding its outlook.
	Saved 2026-09-04 05:23 5d ago Published 2026-09-03 20:00 5d ago	FDA schválila ZANVASTRO pro léčbu Alexanderovy choroby FDA schválila ZANVASTRO od Ionis Pharmaceuticals jako první a jedinou léčbu měnící průběh Alexanderovy choroby u dětí i dospělých. Léčba byla podpořena studií, která splnila hlavní cíl. IT Gartner	FMP Stock News	92
Original source text Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that the U.S. Food and Drug Administration (FDA) has approved ZANVASTRO™ (zilganersen) for the treatment of Alexander disease (AxD) in pediatric and adult patients. ZANVASTRO is the first and only disease modifying treatment for AxD, an ultra-rare, progressive and often fatal neurological disorder that can affect motor, cognitive, autonomic and gastrointestinal function. Until now, treatment of AxD has primarily been limited to managing symptoms. ZANVASTRO is an RNA-targeted medicine designed to address the underlying disease mechanism of AxD by reducing the production of glial fibrillary acidic protein (GFAP). ZANVASTRO 50 mg is administered quarterly as an intrathecal (IT) injection. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260903826844/en/ ZANVASTRO (zilganersen) logo “Today’s approval of ZANVASTRO begins a new chapter for people living with Alexander disease and their families, who have long faced this relentlessly progressive and often fatal disease with no treatment options,” said Brett P. Monia, Ph.D., chief executive officer, Ionis. “This transformative approval also marks our first independent launch from our industry-leading neurology pipeline and underscores the power of our RNA-targeted technology to address serious neurological diseases without adequate treatment options. We are proud to bring this important new treatment to this incredible community and are deeply grateful to the clinical trial participants and their families, regulators, investigators and advocates who helped make this advancement possible.” AxD affects approximately 1 in 1 to 3 million people worldwide. Initial signs of AxD can present from infancy through adulthood and may vary depending on age of onset. As AxD progresses, symptoms may include progressive motor and cognitive dysfunction, a loss of independence and the inability to control muscles for swallowing, airway protection and purposeful movements. AxD is caused by changes in the GFAP gene that lead to the overproduction and toxic accumulation of GFAP in astrocytes. Over time, dysfunction in astrocytes can damage neurons and myelin, which can lead to symptoms commonly associated with AxD. “For decades, care for people living with Alexander disease has focused primarily on managing symptoms, without an option to modify the underlying cause of disease,” said Amy Waldman, M.D., M.S.C.E., pediatric neurologist and lead investigator for the ZANVASTRO study at Children’s Hospital of Philadelphia. “The approval of ZANVASTRO for the treatment of Alexander disease represents a significant advancement in care and opens new possibilities for patients and their families. For the first time, we can move beyond managing individual manifestations of the disease to addressing its underlying biology, with the potential to meaningfully improve outcomes for this community.” “As a mom to a young boy living with Alexander disease and an advocate for this community, I have seen firsthand the profound impact this disease has on individuals and their families. Today’s approval represents a fundamental shift, changing the conversation from ‘How do we manage this disease’ to ‘How can we treat it,’” said Emily Petty, president, End Alexander Disease. “For far too long, receiving a diagnosis of Alexander disease was accompanied by uncertainty and the difficult reality that there were no available treatments. Today, that begins to change. ZANVASTRO marks a defining moment and brings a new sense of possibility to our community.” The FDA approval was based on positive results from the pivotal study of ZANVASTRO in people living with AxD. The pivotal study met its primary endpoint in individuals ≥ 5 years of age, with ZANVASTRO 50 mg demonstrating statistically significant and clinically meaningful stabilization of gait speed as assessed by the 10-Meter Walk Test (10MWT), a commonly used measure of gross motor function in neurologic disease, compared to control at Week 61 (least square mean difference 33.3%, p=0.041). ZANVASTRO also demonstrated improvement in gross motor function in patients 2 to 4 years of age as assessed by the Gross Motor Function Measure-88 (GMFM-88), a well-established motor endpoint, compared to control at Week 61. Secondary and exploratory endpoint results from patient/caregiver- and clinician-reported outcome assessments consistently favored ZANVASTRO. ZANVASTRO demonstrated a favorable safety and tolerability profile, with most adverse events (AEs) being mild or moderate in severity. Serious treatment-emergent adverse events (TEAEs) occurred less frequently in the ZANVASTRO group compared to control. Ionis is committed to helping people access the medicines they are prescribed and will offer a full suite of services for people prescribed ZANVASTRO through Ionis Every Step™. As part of Ionis Every Step, patients will have access to a wide range of support and resources including disease state and product education for patients and caregivers, access to a dedicated Patient Education Manager, assistance with the insurance approval process, information on affordability programs and other ongoing services and resources throughout the treatment journey. Visit ZANVASTRO.com for more information. With the approval of ZANVASTRO, the FDA granted Ionis a Rare Pediatric Disease Priority Review Voucher (PRV), a program designed to incentivize the development of therapies for serious and life-threatening diseases by providing a mechanism to potentially accelerate regulatory review timelines for subsequent applications. ZANVASTRO will be available in the U.S. in the coming weeks. In June 2026, Ionis entered into a license agreement with Recordati, a global pharmaceutical company headquartered in Italy, focused on specialty and rare diseases, under which Recordati obtained exclusive rights to develop and commercialize zilganersen in all countries outside the U.S. Ionis is working closely with Recordati on preparing regulatory submissions in Europe and Japan, which are expected in 2027. Webcast Ionis will hold a webcast on Friday, Sept. 4 at 10:00 a.m. ET to discuss the FDA approval. Interested parties may access the webcast here. A webcast replay will be available for a limited time. IMPORTANT SAFETY INFORMATION WARNINGS AND PRECAUTIONS Aseptic Meningitis If symptoms consistent with aseptic meningitis develop, diagnostic workup and treatment should be initiated according to the standard of care. Adverse reactions of aseptic meningitis (also called chemical meningitis or drug-induced aseptic meningitis) were reported in patients treated with ZANVASTRO during the double-blind and open-label periods of Study 1. One patient experienced a serious adverse reaction of aseptic meningitis during the double-blind treatment period of Study 1, which reoccurred in the open-label extension period and required dose interruption and pretreatment with intravenous dexamethasone prior to subsequent administration of ZANVASTRO. Despite corticosteroid premedication, CSF white blood cell (WBC) and protein increased with continued exposure, but the patient remained asymptomatic and did not require discontinuation from treatment. In addition, nonserious adverse drug reactions of CSF WBC increases have also been reported with ZANVASTRO. ADVERSE REACTIONS Most common adverse reactions (incidence ≥25% patients treated with ZANVASTRO and greater than control) were vomiting, back pain, cough, headache, and post-lumbar puncture syndrome. Patients Less Than 2 Years of Age The adverse reactions of patients less than 2 years of age are expected to be similar to that of pediatric patients 2 years of age and older. Please see full Prescribing Information for ZANVASTRO. About the ZANVASTRO Study The global, multicenter, randomized, double-blind, controlled, multiple-ascending dose (MAD) Phase 1-3 study (NCT04849741) enrolled 54 participants with Alexander disease (AxD) between the ages of 1.5 and 53 years across 13 sites in eight countries. Most participants in the study were children, reflecting the early onset and severe progression of AxD in pediatric populations. Participants were randomized in a 2:1 ratio to receive ZANVASTRO or control for a 60-week double-blind treatment period. The study included two dose cohorts, 25 mg and 50 mg, with the 50 mg dose cohort analyzed as the pivotal dose cohort, with dosing every 12 weeks. At week 60, eligible participants entered a 60-week open-label treatment period, followed by a 120-week open-label long-term extension period. During the long-term extension, participants in the 25 mg dose cohort transitioned to the 50 mg dose cohort. Participants in countries where zilganersen has not been or is not commercially available can continue to receive zilganersen treatment through a 240-week extended long-term extension period, which includes 20 additional doses, followed by a 28-week post-treatment follow-up period. The primary endpoint was percent change from baseline in gait speed as assessed by the 10-Meter Walk Test (10MWT), an assessment of functional mobility, at the end of the double-blind treatment period. Key secondary endpoints include patients' self-identified Most Bothersome Symptom (MBS) Score, change from baseline in Patient Global Impression of Severity (PGIS) Score and Patient Global Impression of Change (PGIC) Score and Clinician Global Impression of Change (CGIC) Score at the end of the double-blind treatment period. About Alexander Disease (AxD) AxD is an ultra-rare, progressive and often fatal neurological disease that occurs in approximately 1 per 1 to 3 million people worldwide and affects a type of cell in the brain called astrocytes. Astrocytes have multiple roles in the brain including support of neurons and oligodendrocytes, which maintain the myelin sheath around nerve fibers. AxD is caused by disease-causing variants in the glial fibrillary acidic protein (GFAP) gene and is generally characterized by progressive neurological deterioration resulting in loss of functional mobility, loss of independence and the inability to control muscles for large movements, swallowing and airway protection, though symptoms can vary depending on age of onset. AxD usually leads to death within 14 - 25 years after symptom onset. About ZANVASTROTM (zilganersen) ZANVASTROTM (zilganersen)is approved by the U.S. Food and Drug Administration (FDA) for the treatment of Alexander disease (AxD) in pediatric and adult patients. ZANVASTRO is an RNA-targeted therapy designed to inhibit production of excess glial fibrillary acidic protein (GFAP) that accumulates as a result of pathogenic variants in the GFAP gene. For more information about ZANVASTRO, visit ZANVASTRO.com. About Ionis Neurology Ionis has been at the forefront of discovering and developing leading neurological disease medicines, including ZANVASTROTM (zilganersen), the only approved treatment for Alexander disease, SPINRAZA® (nusinersen), the first approved treatment for spinal muscular atrophy, WAINUA® (eplontersen), a medicine to treat hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN), and QALSODY® (tofersen) for SOD1-ALS. The clinical-stage portfolio includes 12 investigational medicines, of which seven are wholly owned by Ionis. Ionis' investigational portfolio includes medicines for which there are few or no disease modifying treatments, such as rare diseases including Angelman syndrome, prion disease and multiple system atrophy, as well as more common conditions like Alzheimer's disease. About Ionis Pharmaceuticals, Inc. For more than three decades, Ionis has invented medicines that bring better futures to people with serious diseases. Ionis currently has marketed medicines and a leading pipeline in neurology, cardiometabolic disease and select areas of high patient need. As the pioneer in RNA-targeted medicines, Ionis continues to drive innovation in RNA therapies in addition to advancing new approaches in gene editing. A deep understanding of disease biology and industry-leading technology propels our work, coupled with a passion and urgency to deliver life-changing advances for patients. To learn more about Ionis, visit Ionis.com and follow us on X (Twitter), LinkedIn and Instagram. Ionis Forward-looking Statements This press release includes forward-looking statements regarding Ionis' business and the therapeutic and commercial potential of ZANVASTRO, Ionis' technologies and other products in development and our expectations regarding development and regulatory milestones. Any statement describing Ionis' goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties including those inherent in the process of discovering, developing and commercializing medicines that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such medicines. Ionis' forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements. Although Ionis' forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Ionis. Except as required by law, we undertake no obligation to update any forward-looking statements for any reason. As a result, you are cautioned not to rely on these forward-looking statements. These and other risks concerning Ionis' programs are described in additional detail in Ionis' annual report on Form 10-K for the year ended December 31, 2025, and most recent Form 10-Q, which are on file with the Securities and Exchange Commission. Copies of these and other documents are available from the Company. In this press release, unless the context requires otherwise, "Ionis," "Company," "we," "our" and "us" all refer to Ionis Pharmaceuticals and its subsidiaries. Ionis Pharmaceuticals® is a registered trademark of Ionis Pharmaceuticals, Inc. ZANVASTROTM and Ionis Every StepTM are trademarks of Ionis Pharmaceuticals, Inc. QALSODY® and SPINRAZA® are registered trademarks of Biogen. WAINUA® is a registered trademark of the AstraZeneca group of companies. View source version on businesswire.com: https://www.businesswire.com/news/home/20260903826844/en/
	Saved 2026-09-03 17:14 6d ago Published 2026-09-03 12:31 6d ago	Gartner překonal odhady a zvýšil celoroční výhled na EPS Gartner ve 2. čtvrtletí překonal odhady zisku i tržeb a zvýšil celoroční výhled na EPS na nejméně 14 USD z 13,25 USD. Akcie jsou za měsíc asi o 0,2 % výše. IT Gartner	FMP Stock News	78
Original source text It has been about a month since the last earnings report for Gartner (IT - Free Report) . Shares have added about 0.2% in that time frame, outperforming the S&P 500. Will the recent positive trend continue leading up to its next earnings release, or is Gartner due for a pullback? Well, first let's take a quick look at the latest earnings report in order to get a better handle on the recent drivers for Gartner, Inc. before we dive into how investors and analysts have reacted as of late. Gartner Surpasses Q2 Earnings EstimatesGartner reported better-than-expected second-quarter 2026 results, with both earnings and revenues surpassing the Zacks Consensus Estimate. Adjusted earnings of $4.37 per share beat the consensus estimate of $3.77 by 15.9% and increased 23.8% from the year-ago quarter’s $3.53. The improvement reflected higher operating profit and a considerably lower diluted share count. Revenues of $1.68 billion surpassed the consensus mark of $1.65 billion by 1.8%. Reported revenues declined 0.6% year over year because the prior-year period included revenues from the divested Digital Markets operation. Adjusted revenues increased 2.8% on a reported basis and 1.8% on a foreign-currency-neutral basis. IT’s Contract Value Growth AcceleratesGlobal contract value reached $5.28 billion, increasing 1.7% year over year and 0.3% sequentially on a foreign-currency-neutral basis. The improvement from 1% year-over-year growth in the first quarter indicates that subscription demand is gradually stabilizing. Global Technology Sales contract value was approximately $4 billion, rising 1.1% year over year and remaining nearly flat sequentially. Global Business Sales contract value increased 3.3% year over year and 1.2% sequentially to $1.28 billion. Global wallet retention was 98.2%, up from 97.7% in the preceding quarter but below 101.3% a year earlier. Client retention improved sequentially to 85.2% from 85%, compared with 84.6% in the year-ago quarter. Contract value per enterprise advanced to $414,000 from $376,000 a year ago, partly offsetting a 4.5% decline in client enterprises to 12,775. Gartner’s Q2 Segmental PerformanceInsights revenues increased 2.1% year over year, or 1% on a foreign-currency-neutral basis, to $1.29 billion. Segment contribution rose 4% to $999 million. The contribution margin expanded 150 basis points to 77.5%, demonstrating the scalability of Gartner’s subscription-oriented research platform. Conferences delivered the strongest revenue growth. Segment revenues advanced 15.5% year over year, or 14.2% on a foreign-currency-neutral basis, to $244 million. Contribution jumped 19.6% to $145 million, while the contribution margin expanded 210 basis points to 59.5%. Same-conference revenues increased 12%, although attendee levels declined 1.4%. Gartner held 18 destination conferences during the quarter compared with 19 a year earlier, while destination conference attendance decreased slightly to 28,057 from 28,295. Consulting remained the weakest segment. Revenues declined 8.8% year over year to $142 million, while contribution fell 12.6% to $54 million. The contribution margin contracted 170 basis points to 37.9%. Labor-based consulting revenues decreased 12.8% to $96 million, whereas contract optimization revenues increased 0.9% to $46 million. Consulting backlog rose 9.1% to $214 million, offering some support for future revenues. Billable headcount fell 11.3% to 842, while utilization improved 32 basis points to 65.1%. IT’s Profitability and Cash Flow ImproveAdjusted EBITDA excluding the divested operation increased 6.4% year over year, or 4.4% on a foreign-currency-neutral basis, to $466 million. The corresponding margin expanded 90 basis points to 27.8%. GAAP operating income advanced 15.7% to $378.5 million. The operating margin improved to 22.6% from 19.4% a year earlier, aided by lower service, product-development and administrative expenses. Net income increased 14.4% to $275.5 million. Earnings climbed 33.1% to $4.14 per share, with the faster per-share increase supported by a reduction in shares to 66.6 million from 77.4 million. Operating cash flow rose 3.8% to $398 million. With capital expenditures declining to $20 million from $36 million, free cash flow increased 8.9% to $378 million. The trailing-12-month free cash flow was approximately $1.3 billion. Gartner repurchased 3.6 million shares for $547 million during the quarter. Year-to-date repurchases totaled approximately $1.08 billion. The company had about $1.2 billion remaining under its repurchase authorization as of July 31 after the board approved an additional $500 million in July. Gartner ended the quarter with $1.49 billion in cash and approximately $3 billion in debt. Gross debt to adjusted EBITDA was 1.8 times, while net leverage stood at 0.9 times. Gartner’s 2026 GuidanceGartner now expects 2026 adjusted revenues of at least $6.38 billion, compared with the previous outlook of $6.41 billion. Insights revenues are now projected to be at least $5.17 billion, down from the prior guidance of $5.20 billion. The outlooks for Conferences and Consulting revenues were maintained at no less than $695 million and $510 million, respectively. Despite the revenue adjustment, the company raised its profitability forecast. Adjusted EBITDA excluding the divested operation is now expected to be at least $1.57 billion, up from $1.55 billion. Adjusted EPS guidance for 2026 increased to at least $14 from $13.25, while the free cash flow forecast rose to at least $1.19 billion from $1.16 billion. How Have Estimates Been Moving Since Then?In the past month, investors have witnessed a upward trend in fresh estimates. The consensus estimate has shifted 5.82% due to these changes. VGM ScoresCurrently, Gartner has a average Growth Score of C, though it is lagging a bit on the Momentum Score front with a D. However, the stock was allocated a score of A on the value side, putting it in the top 20% for this investment strategy. Overall, the stock has an aggregate VGM Score of A. If you aren't focused on one strategy, this score is the one you should be interested in. OutlookEstimates have been trending upward for the stock, and the magnitude of these revisions looks promising. It comes with little surprise Gartner has a Zacks Rank #1 (Strong Buy). We expect an above average return from the stock in the next few months. Performance of an Industry PlayerGartner belongs to the Zacks Consulting Services industry. Another stock from the same industry, Equifax (EFX - Free Report) , has gained 4.6% over the past month. More than a month has passed since the company reported results for the quarter ended June 2026. Equifax reported revenues of $1.7 billion in the last reported quarter, representing a year-over-year change of +10.6%. EPS of $2.25 for the same period compares with $2.00 a year ago. For the current quarter, Equifax is expected to post earnings of $2.21 per share, indicating a change of +8.3% from the year-ago quarter. The Zacks Consensus Estimate has changed +0.1% over the last 30 days. The overall direction and magnitude of estimate revisions translate into a Zacks Rank #3 (Hold) for Equifax. Also, the stock has a VGM Score of C.
	Saved 2026-08-31 04:08 9d ago Published 2026-08-25 11:06 15d ago	Gartner roste o 28 % a zvyšuje výhled zisku na akcii (EPS) Gartner za poslední tři měsíce vzrostl o 28,4 % a překonal 13% růst odvětví i index S&P 500. Firma zároveň zvýšila výhled upraveného zisku na akcii (EPS) pro rok 2026 na nejméně 14 USD. IT Gartner	FMP Stock News	78
Original source text Key Takeaways Gartner stock rose 28.4% in three months, outpacing its industry's 13% rally and the S&P 500.Gartner beat Q1 and Q2'26 EPS estimates and lifted its 2026 adjusted EPS outlook to at least $14.Gartner repurchased 3.6M shares for $547M and raised buyback authorization to $1.2B. Gartner, Inc. (IT - Free Report) stock has gained 28.4% over the past three months, outperforming the industry’s 13% rally and the Zacks S&P 500 Composite's marginal return. 3-Month Share Price Performance Image Source: Zacks Investment Research Let us delve deeper into the factors that have contributed to the company’s outperformance. Differentiated Product Portfolio Facilitates Steady RevenueOperating in an industry with low barriers to entry, Gartner has a differentiated product portfolio and an integrated research and consulting team created to serve diverse client requirements best. It provides a competitive edge against its rivals. Leveraging its intellectual capital, Gartner creates and distributes proprietary research content as broadly as possible via published reports, interactive tools, facilitated peer networking, briefings, consultancy and advisory services, and events. These facilitate a steadily improving revenue stream for the company, as evidenced by year-over-year growth of 7.9%, 6.1% and 3.7%. Image Source: Zacks Investment Research Persistent Earnings Beat & Upward Outlook RevisionGartner reported earnings of $3.32 per share during the first quarter of 2026, beating the consensus estimate by 11%. For the second quarter, the company maintained its performance as its earnings beat the consensus estimate by 15.9%. Management’s optimism peaked as it raised the adjusted EPS outlook for 2026 to at least $14 during the second quarter of 2026 from the preceding quarter’s view of at least $13.25. Image Source: Zacks Investment Research Consistency in earnings beats, accompanied by management’s confidence in bottom-line growth, raises shareholder morale, prompting them to invest in the stock. Shareholder-Friendly ActionsGartner executed a significant share repurchase in the second quarter of 2026, amounting to 3.6 million shares for $547 million. It resulted in a sharp 16.2% year-over-year decline in shares outstanding, driving the bottom line by 33.1%. This action underscores management’s focus on creating long-term shareholder value. The board of directors increased buyback authorization by $500 million to $1.2 billion in July 2026, raising investor morale. Zacks Rank & Stocks to ConsiderGartner currently carries a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here. Some higher-ranked stocks in the broader Zacks Business Services sector are The Geo Group (GEO - Free Report) and ScanSource (SCSC - Free Report) , each currently sporting a Zacks Rank #1. The Geo Group has a long-term earnings growth expectation of 14%. GEO delivered a trailing four-quarter earnings surprise of 24.6%, on average. ScanSource has a long-term earnings growth expectation of 15%. SCSC delivered a trailing four-quarter earnings surprise of 7.8%, on average.
	Saved 2026-08-07 19:30 1mo ago Published 2026-08-07 13:11 1mo ago	Gartner zvyšuje EPS a volný peněžní tok, výhled tržeb snižuje Gartner zvýšil výhled upraveného EPS na nejméně 14 USD a volného peněžního toku na nejméně 1,185 miliardy USD, ale snížil výhled upravených tržeb na nejméně 6,375 miliardy USD. Ve 2. čtvrtletí vzrostl upravený EPS o 23,8 % na 4,37 USD. IT Gartner	FMP Stock News	92
Original source text Key Takeaways Gartner raised 2026 adjusted EPS guidance to at least $14 and free cash flow to at least $1.185B.Gartner cut adjusted revenue guidance to at least $6.375B as Consulting revenues fell 8.8% in Q2.Gartner's Q2 adjusted EBITDA margin rose to 27.8%, while buybacks helped adjusted EPS climb 23.8%. Gartner, Inc. (IT - Free Report) raised its 2026 profit and cash-flow expectations even as it lowered its adjusted revenue outlook. The divergence shifts investor attention toward cost control, margins and capital allocation. The key question is whether those levers can keep supporting per-share earnings while top-line growth remains restrained. Gartner Raises Its 2026 Profit ExpectationsGartner lifted adjusted EPS guidance to at least $14 from $13.25. Adjusted EBITDA excluding the divested operation is now expected to reach at least $1.570 billion, up from $1.545 billion previously. Free cash flow guidance also increased to at least $1.185 billion from $1.160 billion. The higher targets point to greater confidence in profitability and cash generation despite a more measured revenue outlook. IT Trims Its Revenue OutlookAdjusted revenue guidance declined to at least $6.375 billion from $6.405 billion. The Insights revenue outlook also moved lower to at least $5.170 billion from $5.200 billion. The simultaneous profit upgrade and revenue reduction puts more weight on operating efficiency and business mix. Gartner said expenses reflect agile cost management while it continues investing in experts and artificial intelligence to support future top-line growth. Gartner’s Q2 Margins Show Why Profits Can RiseSecond-quarter adjusted EBITDA excluding the divested operation increased 6.4% to $466 million. The corresponding margin reached 27.8%, expanding 90 basis points year over year. GAAP operating income rose to $378.5 million from $327.1 million. Operating margin improved to 22.6% from 19.4%, reinforcing the margin expansion behind the higher full-year profit expectations. IT’s Segment Mix Creates Both Support and PressureInsights revenues rose 2.1% to $1.290 billion, while Conferences revenues increased 15.5% to $244 million. Conferences contribution margin reached 59.5%, up from 57.4% a year earlier. Consulting revenues fell 8.8% to $142 million and contribution declined 12.6% to $54 million. Forrester Research, Inc. (FORR - Free Report) , an independent research and advisory firm, is a relevant peer for the Insights business. Accenture plc (ACN - Free Report) , which offers broad consulting and technology services, provides context for Gartner’s Consulting exposure. Gartner’s Cash Flow and Buybacks Add LeverageSecond-quarter free cash flow increased 8.9% to $378 million. Gartner also repurchased 3.6 million shares for $547 million during the quarter, while its board increased the repurchase authorization by $500 million in July. Adjusted EPS rose 23.8% to $4.37, faster than the 6.6% increase in adjusted net income to $291 million. The diluted share count fell to 66.6 million from 77.4 million, showing how buybacks amplified per-share growth. Image Source: Zacks Investment Research IT’s Positive Signals Reinforce the Profit StoryGartner’s raised earnings and free cash flow outlook, wider margins and lower share count support the profit case, but slower revenue expectations keep execution risk in focus. Improvement in Consulting and sustained margin discipline remain important variables. The stock currently carries a Zacks Rank #1 (Strong Buy), You can see the complete list of today’s Zacks #1 Rank stocks here.It carries a Value Score of A and VGM Score of A. It also has a Growth Score of B and Momentum Score of B. The Zacks Rank places IT among the top-ranked stocks based on earnings estimate revisions, while the A and B Style Scores indicate favorable value, growth and momentum characteristics. These signals are positive, but revenue growth and segment execution still warrant monitoring.
	Saved 2026-08-04 12:06 1mo ago Published 2026-08-04 06:00 1mo ago	Gartner zvýšil upravený EPS, tržby klesly Gartner ve 2. čtvrtletí zvýšil upravený EPS na 4,37 USD a čistý zisk na 275 mil. USD, zatímco tržby klesly na 1,676 mld. USD. IT Gartner	FMP Stock News	92
Original source text Diluted EPS: $4.14, +33.1%; Adjusted EPS: $4.37, +23.8% Contract Value, FX Neutral: $5.3 billion, +0.3% Sequentially, +1.7% YoY SECOND QUARTER 2026 HIGHLIGHTS Revenues: $1.7 billion, -0.6% as reported; -1.6% FX neutral. Adjusted Revenues: $1.7 billion, +2.8% as reported; +1.8% FX neutral. Net income: $275 million, +14.4% as reported; Adjusted EBITDA excluding divested operation: $466 million, +6.4% as reported, +4.4% FX neutral. Operating cash flow: $398 million, +3.8%; free cash flow: $378 million, +8.9%. Repurchased 3.6 million common shares for $547 million. Board of Directors increased the share repurchase authorization by $500 million in July 2026. STAMFORD, Conn.--(BUSINESS WIRE)--Gartner, Inc. (NYSE: IT) today reported results for the second quarter of 2026 and updated its financial outlook for the full year 2026. Additional information regarding the Company’s results as well as the updated 2026 financial outlook is provided in an earnings supplement available on the Company’s Investor Relations website at https://investor.gartner.com. Gene Hall, Gartner’s Chairman and Chief Executive Officer, commented, "Contract Value growth accelerated again. Revenues, Adjusted EBITDA excluding divested operation, Adjusted EPS, and free cash flow were ahead of expectations. We repurchased $547 million of stock in the quarter, as our capital allocation continues to create value for our shareholders. In addition, we increased our full year Adjusted EBITDA excluding divested operation, Adjusted EPS, and free cash flow guidance even with the stronger dollar." CONFERENCE CALL INFORMATION The Company will host a webcast call at 8:00 a.m. Eastern time on Tuesday, August 4, 2026 to discuss the Company’s financial results. Listeners can access the webcast live at https://edge.media-server.com/mmc/p/siaqzruh. To participate actively in the live call via dial-in, please register at https://register-conf.media-server.com/register/BI60b3b327155d48c99835471ca69f3102. Once registered, participants will receive a dial-in number and a unique PIN to access the call. A replay of the webcast will be available on the Company’s website for approximately 30 days following the call. CONSOLIDATED RESULTS HIGHLIGHTS (Unaudited; $ in millions, except per share amounts) Three Months Ended June 30, Inc/(Dec) 2026 2025 Inc/(Dec) FX Neutral GAAP Metrics: Revenues $ 1,676 $ 1,686 (0.6 )% (1.6 )% Net income 275 241 14.4 % na Diluted EPS 4.14 3.11 33.1 % na Operating cash flow 398 384 3.8 % na Non-GAAP Metrics: Adjusted revenues $ 1,676 $ 1,631 2.8 % 1.8 % Adjusted EBITDA excluding divested operation 466 438 6.4 % 4.4 % Adjusted EPS 4.37 3.53 23.8 % na Free cash flow 378 347 8.9 % na na=not available. CONTRACT VALUE HIGHLIGHTS Global Technology Sales Contract Value FX Neutral (GTS CV): $4.0 billion, ~flat Sequentially, +1.1% YoY Global Business Sales Contract Value FX Neutral (GBS CV): $1.3 billion, +1.2% Sequentially, +3.3% YoY SEGMENT RESULTS HIGHLIGHTS Our segment results for the three months ended June 30, 2026 were as follows: (Unaudited; $ in millions) Insights Conferences Consulting Revenues $ 1,290 $ 244 $ 142 Inc/(Dec) 2.1 % 15.5 % (8.8 )% Inc/(Dec) - FX neutral 1.0 % 14.2 % (8.8 )% Gross contribution $ 999 $ 145 $ 54 Inc/(Dec) 4.0 % 19.6 % (12.6 )% Contribution margin 77.5 % 59.5 % 37.9 % Additional details regarding our segment results can be obtained from the earnings supplement, our quarterly report on Form 10–Q filed with the SEC on August 4, 2026 and our webcast. Certain financial metrics contained in this Press Release are considered non-GAAP financial measures. Definitions of these non-GAAP financial measures are included in this Press Release under “Non-GAAP Financial Measures” and the related reconciliations are under “Supplemental Information — Non-GAAP Reconciliations.” In this Press Release, some totals may not add due to rounding. The percentage changes are based on the unrounded whole number and recalculation based on millions may yield a different result. ABOUT GARTNER Gartner, Inc. (NYSE: IT) delivers actionable, objective business and technology insights that drive smarter decisions and stronger performance on an organization’s mission-critical priorities. FORWARD-LOOKING STATEMENTS Statements contained in this press release regarding the Company’s growth and prospects, projected financial results, long-term objectives, and all other statements in this release other than recitation of historical facts are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such forward-looking statements involve known and unknown risks, estimates, uncertainties and other factors that may cause actual results to be materially different. Such factors include, but are not limited to, the following: our ability to maintain and expand our products and services; our ability to keep pace with technological and industry developments in artificial intelligence (“AI”) and comply with evolving AI regulations; our ability to achieve continued customer renewals and achieve new contract value, backlog and deferred revenue growth in light of competitive pressures; our ability to grow or sustain revenue from individual customers; our ability to expand or retain our customer base; our ability to carry out our strategic initiatives and manage associated costs; the timing of conferences and meetings, in particular our Gartner Symposium/Xpo series; our ability to achieve and effectively manage growth, including our ability to integrate our acquisitions and consummate and integrate future acquisitions; our ability to attract and retain a professional staff of analysts and consultants as well as experienced sales personnel upon whom we are dependent, especially in light of labor competition; our ability to successfully compete with existing competitors and potential new competitors; our ability to enforce and protect our intellectual property rights; the impact of cybersecurity incidents or other disruptions to our information systems; our ability to pay our debt obligations; the impact of global economic and geopolitical conditions, including inflation (and related monetary policy by governments in response to inflation) and recession; uncertain effects, both direct and indirect, of changes and volatility in tariffs and trade policies; risks associated with the creditworthiness, budget cuts, priorities and shutdown of governments and agencies; additional risks associated with international operations, including foreign currency fluctuations; the impact on our business resulting from changes in international conditions, including those resulting from tensions in the Middle East, the war in Ukraine and current and future sanctions imposed by governments or other authorities; the impact of restructuring and other charges on our businesses and operations; our ability to meet sustainability commitments and comply with applicable regulatory requirements, as well as potential reactions by customers to these commitments; the impact of changes in tax policy (including global minimum tax legislation) and heightened scrutiny from various taxing authorities globally; changes to laws and regulations; and other risks and uncertainties described under “Risk Factors” in our most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, which can be found on Gartner’s website at https://investor.gartner.com and the SEC’s website at www.sec.gov. Forward-looking statements included herein speak only as of the date hereof and Gartner disclaims any obligation to revise or update such statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events or circumstances, except as required by applicable law. NON-GAAP FINANCIAL MEASURES Certain financial measures used in this Press Release are not defined by U.S. generally accepted accounting principles (“GAAP”) and as such are considered non-GAAP financial measures. We provide these measures to enhance the user’s overall understanding of the Company’s current financial performance and the Company’s prospects for the future. Investors are cautioned that these non-GAAP financial measures may not be defined in the same manner by other companies and, as a result, may not be comparable to other similarly titled measures used by other companies. Also, these non-GAAP financial measures should not be construed as alternatives, or superior, to other measures determined in accordance with GAAP. The non-GAAP financial measures used in this Press Release are defined below. Adjusted Revenues: Represents GAAP revenues less revenues from our Digital Markets divested operation. We believe Adjusted Revenues is an important measure of our recurring operations as it provides a more accurate period-over period comparison of trends in revenues. Adjusted EBITDA and Adjusted EBITDA Margin: Represents GAAP net income (loss) adjusted for: (i) interest expense, net; (ii) tax provision (benefit); (iii) gain on event cancellation insurance claims, as applicable; (iv) other (income) expense, net; (v) stock-based compensation expense; (vi) depreciation, amortization, and accretion; (vii) goodwill impairment and other asset impairments, as applicable, (viii) workforce reduction expenses and certain other non-recurring items and (ix) gain/loss on divestitures, as applicable. Adjusted EBITDA Margin represents Adjusted EBITDA divided by GAAP Revenue. We believe Adjusted EBITDA and Adjusted EBITDA Margin are important measures of our recurring operations as they exclude items not representative of our core operating results. Adjusted EBITDA Excluding Divested Operation and Adjusted EBITDA Margin Excluding Divested Operation: Represents Adjusted EBITDA as defined above less EBITDA from our Digital Markets divested operation. Adjusted EBITDA Margin Excluding Divested Operation represents Adjusted EBITDA Excluding Divested Operation divided by Adjusted Revenue. We believe Adjusted EBITDA Excluding Divested Operation and Adjusted EBITDA Margin Excluding Divested Operation are important measures of our recurring operations as it provides a more accurate and consistent period-over period comparison of our results. Adjusted Net Income and Adjusted EPS: Represents GAAP net income (loss) and diluted net income (loss) per share adjusted for the impact of certain items directly related to acquisitions and other non-recurring items. These adjustments include (on a per share basis, in the case of Adjusted EPS): (i) the amortization of acquired intangibles; (ii) workforce reduction expenses and other non-recurring items; (iii) gain on event cancellation insurance claims, as applicable; (iv) the non-cash (gain) loss on de-designated interest rate swaps, as applicable; (v) goodwill impairment and other asset impairments, as applicable, (vi) gain/loss on divestitures, as applicable. and (vii) the related tax impact. We believe Adjusted Net Income and Adjusted EPS are important measures of our recurring operations as they exclude items that may not be indicative of our core operating results. The Company excludes amortization of acquired intangibles because it is generally a fixed non-cash expense that can be significantly impacted by the timing and/or size of acquisitions and management does not use it to evaluate core operating results. Although the Company excludes the amortization of acquired intangibles from Adjusted Net Income and Adjusted EPS, management believes that it is important for investors to understand that such intangible assets were recorded as part of acquisition accounting and contribute to revenue generation. Free Cash Flow: Represents cash provided by operating activities determined in accordance with GAAP less payments for capital expenditures. We believe Free Cash Flow is an important measure of the recurring cash generated by the Company’s core operations that may be available to be used to repay debt obligations, repurchase our stock, invest in future growth through new business development activities, or make acquisitions. Foreign Currency Neutral (FX Neutral): We provide foreign currency neutral dollar amounts and percentages for our contract values, revenues, certain expenses, and other metrics. These foreign currency neutral dollar amounts and percentages eliminate the effects of exchange rate fluctuations and thus provide a more accurate and meaningful trend in the underlying data being measured. We calculate foreign currency neutral dollar amounts by converting the underlying amounts in local currency for different periods into U.S. dollars by applying the same foreign exchange rates to all periods presented. SUPPLEMENTAL INFORMATION - NON-GAAP RECONCILIATIONS The tables below provide reconciliations of certain Non-GAAP financial measures used in this Press Release with the most directly comparable GAAP measure. See “Non-GAAP Financial Measures” above for definitions of these measures. Reconciliation - GAAP Revenues to Adjusted Revenues (Unaudited; $ in millions) Three Months Ended June 30, 2026 2025 Total revenues $ 1,676 $ 1,686 Less: Divested operation revenues — (56 ) Adjusted revenues $ 1,676 $ 1,631 Reconciliation - GAAP Net Income to Adjusted EBITDA Excluding Divested Operation (Unaudited; $ in millions) Three Months Ended June 30, 2026 2025 GAAP net income $ 275 $ 241 Interest expense, net 22 12 Other expense (income), net 2 (2 ) Tax provision 79 77 Operating income 379 327 Adjustments: Stock-based compensation expense (a) 41 43 Depreciation, amortization and accretion (b) 45 51 Loss on impairment of lease related assets (c) — 1 Workforce reduction expenses and other non-recurring items (d) — 22 Gain from sale of divested operation (e) 1 — Adjusted EBITDA $ 466 $ 443 Less: Divested operation adjusted EBITDA (f) — (6 ) Adjusted EBITDA excluding divested operation $ 466 $ 438 (a) Consists of costs for stock-based compensation awards. (b) Includes depreciation expense, amortization of intangibles and accretion on asset retirement obligations. (c) Includes impairment loss for lease related assets. (d) Consists of workforce reduction expenses, direct and incremental expenses related to acquisitions and divestitures, facility-related exit costs and other non-recurring items, if applicable. (e) Consists of an adjustment to the gain from the February 2026 sale of our divested operation. (f) Divested operation adjusted EBITDA is calculated as divested operation contribution minus certain direct Selling, General, and Administrative expenses. It excludes allocations for corporate support services and other indirect costs that benefited the business. Reconciliation - GAAP Net Income and GAAP Net Income per Diluted Share to Adjusted Net Income and Adjusted EPS (Unaudited; $ in millions, except per share amounts) Three Months Ended June 30, 2026 2025 Amount Per Share Amount Per Share GAAP net income and GAAP net income per diluted share $ 275 $ 4.14 $ 241 $ 3.11 Acquisition and other adjustments: Amortization of acquired intangibles (a) 20 0.30 20 0.26 Workforce reduction expenses and other non-recurring items (b), (c) 1 0.02 23 0.29 Gain from sale of divested operation (d) 1 0.01 — — Loss on impairment of lease related assets (e) — — 1 0.01 Tax impact of adjustments (f) (6 ) (0.10 ) (11 ) (0.14 ) Adjusted net income and Adjusted EPS (g) $ 291 $ 4.37 $ 273 $ 3.53 (a) Consists of non-cash amortization from acquired intangibles. (b) Consists of workforce reduction expenses, direct and incremental expenses related to acquisitions and divestitures, facility-related exit costs and other non-recurring items, if applicable. (c) Includes the amortization of deferred financing fees, which are recorded in Interest expense, net in the Company’s accompanying Condensed Consolidated Statements of Operations. (d) Consists of an adjustment to the gain from the February 2026 sale of our divested operation. (e) Includes impairment loss for lease related assets. (f) The blended effective tax rates on the adjustments were approximately 29.1% and 25.5% for the three months ended June 30, 2026 and 2025, respectively. (g) Adjusted EPS was calculated based on 66.6 million and 77.4 million diluted shares for the three months ended June 30, 2026 and 2025, respectively. Reconciliation - GAAP Cash Provided by Operating Activities to Free Cash Flow (Unaudited; $ in millions) Three Months Ended June 30, 2026 2025 GAAP cash provided by operating activities $ 398 $ 384 Cash paid for capital expenditures (20 ) (36 ) Free Cash Flow $ 378 $ 347 GARTNER, INC. Condensed Consolidated Statements of Operations (Unaudited; in millions, except per share data) Three Months Ended June 30, 2026 2025 Revenues: Insights $ 1,289.8 $ 1,263.6 Conferences 244.2 211.4 Consulting 141.9 155.6 Other — 55.9 Total revenues 1,675.9 1,686.5 Costs and expenses: Cost of services and product development 487.0 531.7 Selling, general and administrative 764.6 777.0 Depreciation 25.1 30.5 Amortization of intangibles 20.0 20.2 Gain from sale of divested operation 0.7 — Total costs and expenses 1,297.4 1,359.4 Operating income 378.5 327.1 Interest expense, net (22.3 ) (11.8 ) Other (expense) income, net (1.6 ) 2.5 Income before income taxes 354.6 317.8 Provision for income taxes 79.1 77.0 Net income $ 275.5 $ 240.8 Net income per share: Basic $ 4.14 $ 3.12 Diluted $ 4.14 $ 3.11 Weighted average shares outstanding: Basic 66.5 77.2 Diluted 66.6 77.4 Source: Gartner, Inc. Gartner-IR More News From Gartner, Inc.
	Saved 2026-07-30 18:04 1mo ago Published 2026-07-30 12:15 1mo ago	Gartner čeká pokles tržeb, EPS má vzrůst Gartner čeká ve 2. čtvrtletí pokles tržeb o 2,4 % na 1,7 miliardy USD, zatímco EPS má vzrůst o 6,8 % na 3,77 USD. Nejvíc táhne dolů segment Insights kvůli slabšímu engagementu a retenci. IT Gartner	FMP Stock News	72
Original source text Key Takeaways Gartner's Q2 revenues are expected to fall 2.4% y/y to $1.7 billion as Insights and Consulting weaken.Insights revenues may decline 2.5% as contract value drops 10.7% amid weaker engagement and retention.EPS is projected to rise 6.8% to $3.77, supported by expense management and share repurchases. Gartner Inc. (IT - Free Report) will release second-quarter 2026 results on Aug. 4, before market open. IT has an impressive earnings surprise history. In the four trailing quarters, it surpassed the Zacks Consensus Estimate, with an average surprise of 10.6%. Gartner’s Q2 ExpectationsThe Zacks Consensus Estimate for the top line is pinned at $1.7 billion. It is expected to recede 2.4% from the year-ago quarter’s actual. Revenues are expected to have sunk primarily due to a weaker performance in Insights, which contributes the majority of the top line. A slowdown in Consulting revenues is predicted to have affected the top line. The consensus mark for Insights revenues is $1.3 billion, implying a 2.5% year-over-year decline. We expect the segment to have sustained a blow due to shrinking contract value, as evidenced by a Zacks Consensus Estimate of $4.2 billion, suggesting a 10.7% year-over-year drop. This anticipated cut down in contract value is likely to have stemmed from a slump in client engagement and retention. For Conferences, the Zacks Consensus Estimate is pinned at $218.9 million. The figure is expected to move up 3.5% from the year-ago quarter’s actual. As mentioned by Craig Safian, the CFO, during first-quarter 2026 earnings, Gartner plans to hold 56 in-person destination conferences in 2026. The trajectory to complete these conferences is anticipated to have supported growth. The consensus estimate for Consulting revenues is anticipated to plunge 13.5% year over year. This segment’s revenues are tracking at $134.5 million. Contract optimization is highly variable, which is anticipated to have potentially shifted revenue realization during the second quarter of 2026, affecting this segment. The consensus estimate for earnings per share is $3.77, implying a 6.8% year-over-year escalation. The factors, including agile expense management, leading to margin expansion and continued share repurchases lowering share count, are expected to have supported this upsurge in the bottom line. What Our Model Says About ITOur proven model does not conclusively predict an earnings beat for Gartner this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. But that is not the case here. You can uncover the best stocks before they are reported with our Earnings ESP Filter. IT has an Earnings ESP of -1.48% and a Zacks Rank of 4 (Sell) at present. Stocks to ConsiderHere are a few stocks, according to our model, which have the right combination of elements to beat on earnings this season. Duolingo, Inc. (DUOL - Free Report) : The Zacks Consensus Estimate for second-quarter 2026 revenues is pegged at $297.4 billion, suggesting a 17.9% jump from the year-ago quarter’s actual. For earnings, the consensus mark is set at 61 cents per share, a 33% plunge from the year-ago quarter. DUOL beat the consensus estimate in the trailing four quarters, with an average surprise of 32.3%. DUOL has an Earnings ESP of +9.02% and a Zacks Rank of 2 at present. You can see the complete list of today’s Zacks #1 Rank stocks here. It is scheduled to declare second-quarter 2026 results on Aug. 5. Dave Inc. (DAVE - Free Report) : The Zacks Consensus Estimate for the company’s second-quarter 2026 revenues is $169.8 million, suggesting a 28.9% jump from the year-ago quarter’s actual. For earnings, the consensus mark is $3.69 per share, indicating 17.5% growth. DAVE beat the consensus estimate for earnings in the trailing four quarters, with an average surprise of 45.8%. DAVE has an Earnings ESP of +1.42% and a Zacks Rank of 2 at present. The company is scheduled to declare second-quarter 2026 results on Aug. 5.